<DOC>
	<DOCNO>NCT00199381</DOCNO>
	<brief_summary>This , open-label , long-term safety extension patient North America complete prior istradefylline study 6002-INT-001 .</brief_summary>
	<brief_title>An Extension Istradefylline North American Parkinson 's Disease Patients Who Have Completed Study 6002-INT-001</brief_title>
	<detailed_description>Patients Parkinson 's disease motor complication levodopa therapy complete prior double-blind study 6002-INT-001 eligible enter long-term open safety study start istradefylline dose 20 40mg per day .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>Completion study 6002INT001 Not childbearing potential Cancer within 5 year enrollment ALT/AST level &gt; 2.5 time ULN</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>end dose wear</keyword>
	<keyword>OFF time</keyword>
</DOC>